MYCN and neuroblastoma: Recent studies have shown that ATR inhibition is able to reverse the chemoresistance of ALT (alternative lengthening of telomere) neuroblastoma due to telomere dysfunction–induced ATM activation69, and significantly enhances the efficacy of ALK inhibition in transgenic neuroblastoma models driven by MYCN and ALK70.